



STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: WIN 55,212-3

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled []
Not Controlled [x]

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is an effective antagonist at the CB2 receptor and is not included under item 1 of Schedule II to the CDSA.

Prepared by: Evelyn C Soo Date: October 25th 2010

Verified by: Marianne Tang Date:

Approved by: DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES Date:

This status was requested by: "third party information removed as per agreement with applicant"


Drug Status Report

Drug: WIN 55,212-3

Drug Name Status: WIN 55,212-3 is the common name.

Chemical Name: (S)-(-)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone

Chemical Structure:



Molecular Formula: C₂₇H₂₆N₂O₃

CAS-RN: 131543-25-4

Pharmacological class / Application: Cannabinoid receptor antagonist

International status:

US: The substance is not listed specifically in the CSA and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: WIN 55,212-3 is not currently listed in the Schedules to the CDSA. The substance is a synthetic cannabinoid and an isomer of the cannabinoid receptor agonist WIN 55,212-2. While WIN 55,212-2 has been reported to be an efficacious cannabinoid receptor agonist and deemed to be included under item 1 of Schedule II to the CDSA, WIN 55,212-3 has been shown in the scientific literature to be an efficacious antagonist at the cannabinoid

CB₂ receptor¹. Cannabinoid receptor antagonists have been declared to fall outside the heading “Cannabis, its preparations, derivatives and similar synthetic preparations, including” of item 1 of Schedule II to the CDSA. Therefore, WIN 55,212-3 cannot be included under item 1 of Schedule II to the CDSA.

Recommendation: WIN 55,212-3 is not included in Schedule II to the CDSA and is not a controlled substance.

Date: October 28th 2010

¹Savininen, JR et al. (2005) Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB₂ receptor, Br. J. Pharmacol. **145**:636-645.